Workplace exposure to silica, mold/mildew, and pesticides were associated with an increased risk of pulmonary sarcoidosis in a recent review study. By analyzing data from dozens of published studies, scientists identified more than 80 different airborne factors that have been linked to the disease in at least one study.
Researchers in Austria and the U.K. have created the first mouse model that mimics the human disease of cardiac sarcoidosis. “To our best knowledge this is the first animal model of cardiac sarcoidosis that recapitulates major … hallmarks of human disease,” scientists wrote, adding that it is expected to…
This year’s Global Virtual Sarcoidosis Summit, hosted by the Foundation for Sarcoidosis Research (FSR), is bringing together the sarcoidosis community under the theme “Find Your Community, Find Your Life.” Those interested in taking part in the summit, happening virtually from Nov. 3 to 5, can register…
The Ann Theodore Foundation and the Milken Institute are once again teaming up to offer grants worth up to $3.4 million to help spur research into sarcoidosis. “Varied perspectives and expertise are key to achieving progress in sarcoidosis research, which will then lead to better treatment,” Lisa…
Higher doses of the investigational therapy efzofitimod significantly reduced relapse rates after a dose of a corticosteroid was reduced in people with pulmonary sarcoidosis, according to a new, pooled analysis of Phase 1b/2a trial data. The first-in-class immunomodulatory therapy, developed by aTyr Pharma, also significantly improved lung…
Treatment with tumor necrosis factor-alpha (TNF-a) inhibitors — which block a type of immune protein in the body — was found to ease signs of inflammation and reduce the need for corticosteroids in people with cardiac sarcoidosis in a new analysis. Safety data, meanwhile, indicated that such treatments were…
Most cardiac sarcoidosis patients respond to six months of first-line treatment with the corticosteroid prednisolone and show reduced active inflammation in the heart, according to a small study in Japan. Cardiovascular events were less common among responders relative to those who respondly poorly, further confirming first-line prednisolone’s effectiveness…
Top-line data from an ongoing Phase 2 trial testing Kinevant Sciences’ experimental therapy namilumab in adults with pulmonary sarcoidosis are expected in the second half of 2024. That’s according to a business update from Roivant Sciences, the parent company to Kinevant. Called RESOLVE-Lung (NCT05314517), the…
MRI scans of the heart may help in predicting the risk of cardiac sarcoidosis recurring after initial successful treatment, a study reports. A greater extent of scarred heart tissue prior to treatment, in particular, was associated with a five times higher risk of relapse. The presence of sarcoidosis only…
Death rates while waiting for a lung transplant are disproportionally higher among people with pulmonary sarcoidosis than for those with other lung disorders, a U.S. study shows. “Our research shows that further consideration needs to be given to how we classify patients with sarcoidosis and how we calculate their…
Get regular updates to your inbox.